— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected.
— Total revenue rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose 11% to $3.94 billion.
— For FY20, Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is projected to be $10.65 to $10.85.
— ALXN stock gained 1.8% during pre-market hours immediately following the announcement.
The positive effects of widespread digitalization and e-commerce growth on China’s financial services industry became more pronounced during the pandemic as the movement restrictions drove more retail customers to online
Shares of Activision Blizzard Inc. (NASDAQ: ATVI) were up 1.6% on Thursday. The stock has dropped 14% since the start of the year. The company has been in the news
The emergence of technology-driven financial services is making people think beyond conventional banks when it comes to availing loans and transferring funds. In a move aimed at taking its business